trending Market Intelligence /marketintelligence/en/news-insights/trending/4fc16KL1PZ3MYZi5lhILTQ2 content esgSubNav
In This List

Report: CSPC Pharmaceutical drug ingredient placed on Chinese watch list

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Report: CSPC Pharmaceutical drug ingredient placed on Chinese watch list

CSPC Pharmaceutical Group Ltd.'s shares slumped on speculation that butylphthalide, a substance used in one of the company's key medicines, has been included on a watch list in China's eastern Zhejiang province, Bloomberg News reported.

The Chinese drugmaker's shares were down 6.10% to HK$16.02 as of market close Oct. 11. Butylphthalide is used in China to treat stroke, although it has not been proven to be effective in that indication.

The inclusion would put the usage of the ingredient under scrutiny and eat into CSPC's sales. CSPC uses butylphthalide to manufacture NBP soft capsule and NBP injections to treat acute ischemic strokes, a condition that causes the brain to not function properly, leading to loss of neurologic function.

CSPC generated 11.18 billion yuan in revenues during the first six months of the year, up 27.6% year over year thanks to strong growth in sales of innovative drugs.

Innovative drug sales surged 55.4% year over year to 6.15 billion yuan during that same period, and sales of NBP had increased by 35.9%.

As of Oct. 10, US$1 was equivalent to 7.12 Chinese yuan.